Moreover, survivin-specific CTLs have been demonstrated to sufficiently recognize and kill survivin- and HLA-A2-positive leukemia cells in patients with AML, without cross-reactivity against healthy progenitor cells (68). This evidence concerns the gene BIRC5 and leukemia.